78 related articles for article (PubMed ID: 3978661)
1. Phase II evaluation of bisantrene in metastatic breast cancer.
Cavalli F; Gerard B; ten Bokkel Huinink W; Clavel M; Rozencweig M
Cancer Treat Rep; 1985 Mar; 69(3):337-8. PubMed ID: 3978661
[No Abstract] [Full Text] [Related]
2. Bisantrene, an active drug in patients with advanced breast cancer.
Osborne CK; Von Hoff DD; Cowan JD; Sandbach J
Cancer Treat Rep; 1984 Feb; 68(2):357-60. PubMed ID: 6697324
[TBL] [Abstract][Full Text] [Related]
3. Bisantrene, an active new drug in the treatment of metastatic breast cancer.
Yap HY; Yap BS; Blumenschein GR; Barnes BC; Schell FC; Bodey GP
Cancer Res; 1983 Mar; 43(3):1402-4. PubMed ID: 6825109
[TBL] [Abstract][Full Text] [Related]
4. Phase II evaluation of bisantrene in patients with advanced renal cell carcinoma.
Evans WK; Shepherd FA; Blackstein ME; Osoba D; Taylor D
Cancer Treat Rep; 1985 Jun; 69(6):727-8. PubMed ID: 4016779
[No Abstract] [Full Text] [Related]
5. Phase II trial of bisantrene in patients with advanced sarcoma: a Southwest Oncology Group Study.
Cowan JD; Gehan E; Rivkin SE; Jones SE
Cancer Treat Rep; 1986 May; 70(5):685-6. PubMed ID: 3708622
[No Abstract] [Full Text] [Related]
6. Chemotherapy in metastatic melanoma: phase II studies of amsacrine, mitoxantrone and bisantrene.
Coates AS; Bishop J; Mann GJ; Raghavan D
Eur J Cancer Clin Oncol; 1986 Jan; 22(1):97-100. PubMed ID: 3754214
[TBL] [Abstract][Full Text] [Related]
7. Phase I clinical investigation of 9,10-anthracenedicarboxaldehyde bis[(4,5-dihydro-1H-imidazol-2-yl)hydrazone] dihydrochloride with correlative in vitro human tumor clonogenic assay.
Alberts DS; Mackel C; Pocelinko R; Salmon SE
Cancer Res; 1982 Mar; 42(3):1170-5. PubMed ID: 7037174
[TBL] [Abstract][Full Text] [Related]
8. Phase II trial of Bisantrene for metastatic melanoma: an Illinois cancer council study.
Stiff PJ; Sweet D; Kilton LJ; Johnson CM; Muntean B; Blough RR
Med Pediatr Oncol; 1991; 19(2):126-8. PubMed ID: 2011097
[TBL] [Abstract][Full Text] [Related]
9. Treatment of advanced non-small cell lung cancer with bisantrene.
Fuks JZ; Van Echo DA; Garbino C; Kasdorf H; Aisner J
Cancer Treat Rep; 1983 Jun; 67(6):597-8. PubMed ID: 6305499
[No Abstract] [Full Text] [Related]
10. Phase II trial of bisantrene in patients with metastatic melanoma.
Mackel C; Meyskens FL; Alberts DS
Cancer Treat Rep; 1986 Aug; 70(8):1037-8. PubMed ID: 3731151
[No Abstract] [Full Text] [Related]
11. Phase II trial of 6-thioguanine in metastatic breast cancer.
Pandya KJ; Tormey DC; Davis TE; Falkson G; Banerjee TK; Crowley J
Cancer Treat Rep; 1980 Jan; 64(1):191-2. PubMed ID: 7379055
[No Abstract] [Full Text] [Related]
12. Bisantrene in non-small cell lung cancer: a phase II trial of the Cancer and Leukemia Group B.
Green MR; Vosika G; Propert KJ; Ware JH; Comis R
Cancer Treat Rep; 1986 Apr; 70(4):539-40. PubMed ID: 3698052
[No Abstract] [Full Text] [Related]
13. Phase II evaluation of bisantrene in patients with renal cell carcinoma.
Myers JW; Von Hoff DD; Coltman CA; Kuhn JG; Van Echo D; Rivkin S; Pocelinko R
Cancer Treat Rep; 1982 Oct; 66(10):1869-71. PubMed ID: 7127326
[No Abstract] [Full Text] [Related]
14. Phase II evaluation of methyl-GAG in patients with refractory metastatic breast cancer.
Yap HY; Blumenschein GR; Schell F; Bodey GP
Cancer Treat Rep; 1981; 65(5-6):465-7. PubMed ID: 7237467
[TBL] [Abstract][Full Text] [Related]
15. Second-line chemotherapy with tauromustine in metastatic breast cancer in postmenopausal women: a phase II study.
Ernst P; Balslev I; Mouridsen HT
Cancer Treat Rep; 1987 Oct; 71(10):987-8. PubMed ID: 3652062
[No Abstract] [Full Text] [Related]
16. Disposition of bisantrene in humans and rabbits: evidence for intravascular deposition of drug as a cause of phlebitis.
Powis G; Kovach JS
Cancer Res; 1983 Feb; 43(2):925-9. PubMed ID: 6848203
[TBL] [Abstract][Full Text] [Related]
17. Phase II trial of bisantrene for advanced hypernephroma.
Scher H; Schwartz S; Yagoda A; Watson R; Faye L
Cancer Treat Rep; 1982 Aug; 66(8):1653-5. PubMed ID: 7105056
[No Abstract] [Full Text] [Related]
18. Evaluation of bisantrene administered by 72-hour infusion in women with metastatic breast cancer.
Ingle JN; Long HJ; Schutt AJ; Chang MN
Am J Clin Oncol; 1986 Oct; 9(5):379-81. PubMed ID: 3776899
[TBL] [Abstract][Full Text] [Related]
19. Phase II evaluation of procarbazine in metastatic breast cancer: a Southeastern Cancer Study Group Trial.
Carpenter JT; Raney M; Logan T
Cancer Treat Rep; 1986 May; 70(5):679-80. PubMed ID: 3708619
[No Abstract] [Full Text] [Related]
20. Phase II trial of bisantrene in advanced colorectal carcinoma.
Ahmed T; Kemeny NE; Michaelson RA; Harper HD
Cancer Treat Rep; 1983 Mar; 67(3):307-8. PubMed ID: 6831479
[No Abstract] [Full Text] [Related]
[Next] [New Search]
